结合疗法在CLL中的有效性和挑战
Majed A Alanazi1, Faith A A Kwa2, Musab M A Omar3
1Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC, Australia; Ministry of Education, Riyadh, Saudi Arabia.
本综述涵盖慢性淋巴细胞白血病 (CLL) 病理生理学,遗传学以及诸如布鲁顿氨酸激酶 (BTK) 和B细胞淋巴瘤2 (BCL2) 抑制剂等治疗方法. 它强调了挑战和需要创新的策略来改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是一个成熟的单克隆B淋巴细胞扩张.
- 这种类型的CLL会影响二次性淋巴细胞器官,血液和骨髓.
- 了解CLL病理生理学对于有效治疗至关重要.
研究的目的:
- 提供对CLL的深入审查.
- 强调病理生理学,细胞发生变化和治疗策略.
- 探索新疗法的有效性和挑战.
主要方法:
- 关于CLL病理生理学的文献综述.
- 对CLL中细胞因子变化的分析.
- 评估布鲁顿氨酸激酶 (BTK),B细胞淋巴瘤2 (BCL2) 和酸丁 3-激酶 (PI3K) 抑制剂.
- 单疗法和组合疗法疗效的比较.
主要成果:
- 像BTK,BCL2和PI3K抑制剂这样的新疗法显示出希望,但面临挑战.
- 治疗的有效性因患者的反应而异.
- 了解耐药机制是管理化学耐药性和不耐受性的关键.
结论:
- 需要创新的策略来克服CLL的治疗耐药性.
- 优化治疗方案可以提高患者的治疗结果.
- 需要进一步的研究,以充分阐明新药在CLL管理中的作用.
更多相关视频
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drug Therapy
Antianxiety Medications
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
